People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sermonix Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $42.8M | $878.7M | 2021 |
Paul Plourde at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Plourde on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Friedman | 1 | 4 |
| Anthony Wild | 1 | 3 |
| Simon Jenkins | 1 | 2 |
| Patrick Wiesel | 1 | 1 |
| David Portman | 1 | 1 |
| Miriam Portman | 1 | 1 |
| Elizabeth Attias | 1 | 1 |
| Elizabeth Garner | 1 | 1 |
| Richard De Schutter | 1 | 1 |
| Barry Komm | 1 | 1 |
| Thomas Pfisterer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.